The effects of alpha stimulation and alpha blockade on pulmonary vascular segment resistance in canine cardiogenic shock.
D000316:Adrenergic alpha-Agonists / Q000494:pharmacology*; D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology*; D000818:Animals; D001794:Blood Pressure; D002200:Capillary Resistance / Q000187:drug effects; D004195:Disease Models, Animal; D004285:Dogs; D004837:Epinephrine / Q000008:administration & dosage / Q000494:pharmacology; D007263:Infusions, Parenteral; D009638:Norepinephrine / Q000008:administration & dosage / Q000494:pharmacology; D010643:Phenoxybenzamine / Q000008:administration & dosage / Q000494:pharmacology; D011651:Pulmonary Artery / Q000503:physiopathology; D011652:Pulmonary Circulation / Q000187:drug effects*; D011667:Pulmonary Veins / Q000503:physiopathology; D012770:Shock, Cardiogenic / Q000188:drug therapy* / Q000503:physiopathology; D013564:Sympathetic Nervous System / Q000503:physiopathology*; D014655:Vascular Resistance / Q000187:drug effects*; D014666:Vasomotor System / Q000503:physiopathology
D000316:Adrenergic alpha-Agonists; D000317:Adrenergic alpha-Antagonists; D010643:Phenoxybenzamine; D009638:Norepinephrine; D004837:Epinephrine